An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis
Phase 2
Completed
NCT02565810
| Condition | Rheumatoid Arthritis |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Samsung Bioepis Co., Ltd. |
|---|
| Status | Completed |
|---|
| Enrollment | 49 participants |
|---|
| Interventions | Adalimumab PFS and Pen |
|---|
| Start date | Sep, 2015 |
|---|
| Completion date | Mar, 2016 |
|---|
| Results posted | Apr 1, 2019 |
|---|
Summary
A study comparing the use of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects with Rheumatoid Arthritis.
The Change in Injection Site Pain Score Using an 11-point Visual Numeric Scale
Difference of injection site pain score (Week 6 - Week 2) · Difference (scores on a scale)
| SB5 Pen/PFS | -0.35 Difference (scores on a scale) |
|---|
| SB5 Pen/PFS | -0.11 Difference (scores on a scale) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.